S

Sanofi

Global pharma company; vaccines and R&D

Events & Engagements Specialist - French-speaking

Full-TimeDeadline 10/31/26
HUF7.6M - HUF11.4M
Junior, Mid
Bachelor's
Budapest, Hungary
HybridThree days in the office and two days at home per week.
Project & Program ManagementProject Management

About the job

Requirements
  • A minimum of 1–3 years of experience in event planning, contracting, or operational support is required.
  • Proficiency in the Microsoft Office suite is required.
  • Strong stakeholder engagement is required.
  • Attention to detail, customer orientation, and adaptability are required.
  • Ability to work independently in a fast-paced, multicultural environment with urgency and accountability is required.
  • A bachelor's degree is required.
  • Excellent spoken and written English is required.
  • Excellent spoken and written French is required.
Responsibilities
  • Partner directly or through third-party agencies with transversal brand teams, creative agencies, healthcare organizations, associations, and exhibit vendors to deliver end-to-end event experiences that meet or exceed stakeholder expectations.
  • Provide input on site selection, service contractors, contract negotiation, and budget planning; facilitate vendor selection; follow company policies, particularly those related to transparency and compliance; manage remote meetings through local vendors; and provide technical and analytical support for hybrid and virtual meetings.
  • Coordinate hotel accommodations and services, transportation, communications and facilities support, program functions, and related activities, directly or through a third-party agency.
  • Plan and monitor meetings, identify risks early, and establish risk-mitigation plans; oversee program logistics including attendee registration and data management, food and beverage selection, speaker communications, audiovisual needs, and off-site venues; and occasionally provide hands-on program management.
  • Manage budgets, financial reconciliation, and post-meeting reporting to identify synergies and cost efficiencies; serve as the subject-matter expert for implementation and training of technology solutions and attendee-data analysis; and provide technical support and troubleshooting for One Sanofi platforms such as SpotMe and Cvent, as well as other meeting technology solutions.
  • Depending on event type, oversee or manage activities related to scientific external expert, healthcare organization, or patient engagement for event-related services, from creation of the event or engagement through approval, invitations, contract signatures, financial approvals, post-event invoicing, and transparency disclosures.
  • Provide input to the Global Rationale Form when required for event and engagement approval.
  • Create and support completion of service agreements using One Sanofi tools and platforms; manage reviews and approvals through the One Sanofi transparency approval and reporting tool; and coordinate agreement signatures with external and internal parties, including the Contract Management team for complex agreements.
  • Manage financial approvals and post-event invoice payments.
  • Monitor and report follow-up actions and planning status for scientific external expert and healthcare organization engagements; update related budgets and forecasts; and deliver end-to-end event planning, implementation, and tracking for stakeholders.
  • Share knowledge and best practices with peers and stakeholders and develop working relationships through transparent communication.
  • Evaluate vendor and partner services and processes to help ensure obligations are met or exceeded, and provide timely and accurate metrics on event-management success, transparency, and compliance.
Desired Qualifications
  • Hands-on experience with Veeva Vault CRM, Cvent, or similar event or contracting platforms is strongly preferred.
  • Experience in the pharmaceutical or life sciences industry, or other regulated markets, is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...